Acrivon Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

595.23 k

Shareholding (Mar 2025)

FII

1.89%

Held by 24 FIIs

DII

81.72%

Held by 9 DIIs

Promoter

9.55%

How big is Acrivon Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Acrivon Therapeutics, Inc. has a market capitalization of 37.94 million, with net sales of 0.00 million and a net profit of -83.75 million over the last four quarters. The company reported shareholder's funds of 176.79 million and total assets of 196.59 million as of Dec 24.

What does Acrivon Therapeutics, Inc. do?

22-Jun-2025

Acrivon Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $20 million and a market cap of $37.94 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -52.22%.

Is Acrivon Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Acrivon Therapeutics shows a mildly bullish technical trend with mixed signals across indicators, having outperformed the S&P 500 recently, but facing significant negative returns year-to-date and over the past year.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 56 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.95

Return on Equity

-60.09%

Price to Book

0.39

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-21 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

79.85%

6 Months

107.76%

1 Year

-67.65%

2 Years

-45.35%

3 Years

-80.95%

4 Years

0.0%

5 Years

0.0%

Acrivon Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Acrivon Therapeutics, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Acrivon Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The RSI shows a bullish signal on the monthly timeframe, but no signal on the weekly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are mildly bearish, and the KST is bearish weekly with no monthly signal. Dow Theory shows no trend weekly and mildly bullish monthly. OBV is bullish in both weekly and monthly perspectives. In terms of performance, Acrivon has outperformed the S&P 500 over the past week and month, with returns of 7.74% and 20.14% respectively, while the S&P 500 returned 1.05% and 2.33%. However, year-to-date and one-year returns are significantly negative at -72.26% and -77.91%, compared to the S&P 500's positive returns of 12.22% and 17.14%...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-347.26%

EBIT to Interest (avg)

-41.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.93

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

78.29%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.26

EV to EBIT

1.14

EV to EBITDA

1.15

EV to Capital Employed

-8.95

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-52.22%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

Bullish

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 19 Schemes (6.84%)

Foreign Institutions

Held by 24 Foreign Institutions (1.89%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -11.70% vs -35.25% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.30",
          "val2": "-21.20",
          "chgp": "-5.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.00",
          "val2": "-18.80",
          "chgp": "-11.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -33.44% vs -93.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-88.20",
          "val2": "-66.70",
          "chgp": "-32.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-80.60",
          "val2": "-60.40",
          "chgp": "-33.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-22.30

-21.20

-5.19%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-21.00

-18.80

-11.70%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -11.70% vs -35.25% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-88.20

-66.70

-32.23%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-80.60

-60.40

-33.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -33.44% vs -93.59% in Dec 2023

All Annual Results

Company CV

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Acrivon Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Acrivon Therapeutics, Inc.?

Watch in Real-Time

What does Acrivon Therapeutics, Inc. do?

Is Acrivon Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Acrivon Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Acrivon Therapeutics, Inc.

Company Coordinates